{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:35:59Z","timestamp":1790501759601,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Nonsense mutations that lead to the insertion of a premature termination codon (PTC) in the cystic fibrosis transmembrane conductance regulator (CFTR) transcript affect 11% of patients with cystic fibrosis (CF) worldwide and are associated with severe disease phenotype. While CF rat models have contributed significantly to our understanding of CF disease pathogenesis, there are currently no rat models available for studying CF nonsense mutations. Here we created and characterized the first homozygous CF rat model that bears the CFTR G542X nonsense mutation in the endogenous locus using CRISPR\/Cas9 gene editing. In addition to displaying severe CF manifestations and developmental defects such as reduced growth, abnormal tooth enamel, and intestinal obstruction, CFTR G542X knockin rats demonstrated an absence of CFTR function in tracheal and intestinal sections as assessed by nasal potential difference and transepithelial short-circuit current measurements. Reduced CFTR mRNA levels in the model further suggested sensitivity to nonsense-mediated decay, a pathway elicited by the presence of PTCs that degrades the PTC-bearing transcripts and thus further diminishes the level of CFTR protein. Although functional restoration of CFTR was observed in G542X rat tracheal epithelial cells in response to single readthrough agent therapy, therapeutic efficacy was not observed in G542X knockin rats<jats:italic>in vivo<\/jats:italic>. The G542X rat model provides an invaluable tool for the identification and<jats:italic>in vivo<\/jats:italic>validation of potential therapies for CFTR nonsense mutations.<\/jats:p>","DOI":"10.3389\/fphys.2020.611294","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T13:54:47Z","timestamp":1610286887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay"],"prefix":"10.3389","volume":"11","author":[{"given":"Jyoti","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Klaskala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Birket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/154405910208100712","article-title":"Cystic fibrosis transmembrane regulator gene (CFTR) is associated with abnormal enamel formation.","volume":"81","author":"Arquitt","year":"2002","journal-title":"J. Dent. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1172\/jci7866","article-title":"Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.","volume":"104","author":"Barton-Davis","year":"1999","journal-title":"J. Clin. Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line.","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat. Med."},{"key":"B4","doi-asserted-by":"crossref","first-page":"L928","DOI":"10.1152\/ajplung.00395.2015","article-title":"Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.","volume":"310","author":"Birket","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97199","article-title":"Development of an airway mucus defect in the cystic fibrosis rat.","volume":"3","author":"Birket","year":"2018","journal-title":"JCI Insight"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1164\/rccm.202002-0369oc","article-title":"Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.","volume":"202","author":"Birket","year":"2020","journal-title":"Am. J. Respir. Critic. Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1534\/genetics.110.117002","article-title":"Targeted genome modification in mice using zinc-finger nucleases.","volume":"186","author":"Carbery","year":"2010","journal-title":"Genetics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev.biochem.76.050106.093909","article-title":"The nonsense-mediated decay RNA surveillance pathway.","volume":"76","author":"Chang","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"modulator theratyping: Current status, gaps and future directions.","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1165\/rcmb.2006-0173oc","article-title":"No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.","volume":"37","author":"Clancy","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/humu.23692","article-title":"The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis.","volume":"40","author":"Clarke","year":"2019","journal-title":"Hum. Mutat."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1126\/science.257.5073.1125","article-title":"Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis.","volume":"257","author":"Clarke","year":"1992","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1073\/pnas.88.20.9262","article-title":"Immunocytochemical localization of the cystic fibrosis gene product CFTR.","volume":"88","author":"Crawford","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.","volume":"379","author":"Davies","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lpm.2017.04.010","article-title":"The diagnosis of cystic fibrosis.","volume":"46","author":"De Boeck","year":"2017","journal-title":"Presse Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr-\/- mouse carrying a human CFTR-G542X transgene.","volume":"80","author":"Du","year":"2002","journal-title":"J. Mol. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00109-006-0045-5","article-title":"Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.","volume":"84","author":"Du","year":"2006","journal-title":"J. Mol. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/mus.10341","article-title":"Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle.","volume":"27","author":"Dunant","year":"2003","journal-title":"Muscle Nerve"},{"key":"B19","first-page":"106","article-title":"Dental enamel defects in Italian children with cystic fibrosis: an observational study.","volume":"29","author":"Ferrazzano","year":"2012","journal-title":"Communit. Dent. Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00109-007-0275-1","article-title":"Incomplete nonsense-mediated decay of mutant lamin A\/C mRNA provokes dilated cardiomyopathy and ventricular tachycardia.","volume":"86","author":"Geiger","year":"2008","journal-title":"J. Mol. Med."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/rcmb.2006-0184TR","article-title":"Cystic fibrosis mouse models.","volume":"36","author":"Guilbault","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.23773","article-title":"Toward inclusive therapy with CFTR modulators: Progress and challenges.","volume":"52","author":"Guimbellot","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ana.20052","article-title":"Readthrough of dystrophin stop codon mutations induced by aminoglycosides.","volume":"55","author":"Howard","year":"2004","journal-title":"Ann. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.","volume":"2","author":"Howard","year":"1996","journal-title":"Nat. Med."},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1386-9","article-title":"Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations.","volume":"19","author":"Huang","year":"2018","journal-title":"Genome Biol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186984","article-title":"Use of ferrets for electrophysiologic monitoring of ion transport.","volume":"12","author":"Kaza","year":"2017","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060478","article-title":"Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.","volume":"8","author":"Keeling","year":"2013","journal-title":"PLoS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough.","volume":"15","author":"Keeling","year":"2014","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"B29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0b013e32834b14c9","article-title":"New animal models of cystic fibrosis: what are they teaching us?","volume":"17","author":"Keiser","year":"2011","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nrm3454","article-title":"a multifaceted response to premature translational termination.","volume":"13","author":"Kervestin","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1089\/hum.2016.009","article-title":"CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA. RNA, and Protein into Cultured Cells and Single-Cell Embryos.","volume":"27","author":"Kouranova","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-1-61779-117-8_10","article-title":"Nonsense-mediated mRNA decay and cystic fibrosis.","volume":"741","author":"Linde","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/jci28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.","volume":"117","author":"Linde","year":"2007","journal-title":"J. Clin. Invest."},{"key":"B34","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.","volume":"67","author":"Malik","year":"2010","journal-title":"Ann. Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1017\/s1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm1310","article-title":"Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics.","volume":"5","author":"Maquat","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1164\/rccm.201805-0827le","article-title":"Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats.","volume":"198","author":"McCormick","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199573","article-title":"A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies.","volume":"13","author":"McHugh","year":"2018","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.jpedsurg.2017.11.040","article-title":"Long-term intestinal obstruction sequelae and growth in children with cystic fibrosis operated for meconium ileus: expectancies and surprises.","volume":"53","author":"Mentessidou","year":"2018","journal-title":"J. Pediatr. Surg."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1164\/rccm.201004-0643oc","article-title":"Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children.","volume":"182","author":"Meyerholz","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity.","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/00041552-199707000-00013","article-title":"Cell biology of aminoglycoside nephrotoxicity: newer aspects.","volume":"6","author":"Molitoris","year":"1997","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1042\/bcj20180044","article-title":"transcription factor network represses CFTR gene expression in airway epithelial cells.","volume":"475","author":"Mutolo","year":"2018","journal-title":"Biochem. J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1164\/rccm.201601-0154oc","article-title":"Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.","volume":"194","author":"Mutyam","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/ppul.24764","article-title":"Ataluren\/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.","volume":"55","author":"Peabody Lever","year":"2020","journal-title":"Pediatric pulmonology"},{"key":"B47","first-page":"15","article-title":"Gentamicin administration in Duchenne patients with premature stop codon.","volume":"22","author":"Politano","year":"2003","journal-title":"Prelim. Results Acta Myol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1165\/rcmb.2009-0281oc","article-title":"Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of DeltaF508 cystic fibrosis transmembrane conductance regulator rescue.","volume":"43","author":"Pyle","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i859","article-title":"New and emerging targeted therapies for cystic fibrosis.","volume":"352","author":"Quon","year":"2016","journal-title":"BMJ"},{"key":"B50","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"potentiator in patients with cystic fibrosis and the G551D mutation.","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"B52","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.1163600","article-title":"Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs.","volume":"321","author":"Rogers","year":"2008","journal-title":"Science"},{"key":"B53","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis.","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00109-011-0787-6","article-title":"Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.","volume":"89","author":"Rowe","year":"2011","journal-title":"J. Mol. Med."},{"key":"B55","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17476348.2018.1507741","article-title":"Tezacaftor for the treatment of cystic fibrosis.","volume":"12","author":"Sala","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4103\/0300-1652.193861","article-title":"Gentamicin-mediated ototoxicity and nephrotoxicity: A clinical trial study.","volume":"57","author":"Saleh","year":"2016","journal-title":"Niger. Med. J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jcf.2004.05.039","article-title":"Animal models of cystic fibrosis.","volume":"3","author":"Scholte","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1164\/rccm.201001-0137oc","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112436","article-title":"Pharmacological approaches for targeting cystic fibrosis nonsense mutations.","volume":"200","author":"Sharma","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007723","article-title":"Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis.","volume":"14","author":"Sharma","year":"2018","journal-title":"PLoS Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.febslet.2008.12.058","article-title":"The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision?","volume":"583","author":"Silva","year":"2009","journal-title":"FEBS Lett."},{"key":"B62","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/s0272-6386(86)80103-2","article-title":"Studies of risk factors for aminoglycoside nephrotoxicity.","volume":"8","author":"Smith","year":"1986","journal-title":"Am. J. Kidney Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1126\/science.257.5073.1083","article-title":"An animal model for cystic fibrosis made by gene targeting.","volume":"257","author":"Snouwaert","year":"1992","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1378\/chest.10-0179","article-title":"An international randomized multicenter comparison of nasal potential difference techniques.","volume":"138","author":"Solomon","year":"2010","journal-title":"Chest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188497","article-title":"Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient rat.","volume":"12","author":"Stalvey","year":"2017","journal-title":"PLoS One"},{"key":"B66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejphar.2015.03.070","article-title":"Animal models of Parkinsons disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).","volume":"761","author":"Stasi","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jcmm.12744","article-title":"Tissue-specific variation in nonsense mutant transcript level and drug-induced read-through efficiency in the Cln1(R151X) mouse model of INCL.","volume":"20","author":"Thada","year":"2016","journal-title":"J. Cell Mol. Med."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091253","article-title":"Characterization of Defects in Ion Transport and Tissue Development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Knockout Rats.","volume":"9","author":"Tuggle","year":"2014","journal-title":"PLoS One"},{"key":"B69","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator. VX-770.","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S1569-1993(11)60020-9","article-title":"Mouse models of cystic fibrosis: phenotypic analysis and research applications.","volume":"10","author":"Wilke","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00117","article-title":"Class 1 CF Mutations.","volume":"3","author":"Wilschanski","year":"2012","journal-title":"Front. Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1056\/nejmoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1177\/00220345960750041101","article-title":"Abnormal enamel development in a cystic fibrosis transgenic mouse model.","volume":"75","author":"Wright","year":"1996","journal-title":"J. Dent. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1165\/rcmb.2013-0282oc","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.","volume":"50","author":"Xue","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2156-9-83","article-title":"Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues.","volume":"9","author":"Zetoune","year":"2008","journal-title":"BMC Genet."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2020.611294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:00:30Z","timestamp":1697533230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2020.611294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":77,"alternative-id":["10.3389\/fphys.2020.611294"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2020.611294","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]},"article-number":"611294"}}